Loss of Hepatic Angiotensinogen Attenuates Sepsis-Induced Myocardial Dysfunction

Circ Res. 2021 Aug 20;129(5):547-564. doi: 10.1161/CIRCRESAHA.120.318075. Epub 2021 Jul 9.

Jiabing Rong^#^{1

2}, Xinran Tao^#³, Yao Lin⁴, Haiqiong Zheng^{1

2}, Le Ning¹, Hong S Lu⁵, Alan Daugherty⁵, Peng Shi^{1

6

2}, Adam E Mullick⁷, Sicong Chen⁸, Zhaocai Zhang⁴, Yinchuan Xu^{1

2}, Jian'an Wang^{1

2}

¹ Departments of Cardiology (J.R., H.Z., L.N., P.S., Y.X., J.W.), Zhejiang University School of Medicine, Hangzhou, China.
² Cardiovascular Key Laboratory of Zhejiang Province, Hangzhou, China (J.R., H.Z., P.S., Y.X., J.W.).
³ The Second Affiliated Hospital, Department of Cardiology, The First Affiliated Hospital (X.T.).
⁴ Intensive Care Unit (Y.L., Z.Z.), Zhejiang University School of Medicine, Hangzhou, China.
⁵ Saha Cardiovascular Research Center, Department of Physiology, University of Kentucky, Lexington, KY (H.S.L., A.D.).
⁶ Institute of Translational Medicine (P.S.), Zhejiang University School of Medicine, Hangzhou, China.
⁷ Ionis Pharmaceuticals, Carlsbad, CA (A.E.M.).
⁸ Clinical Research Center (S.C.), Zhejiang University School of Medicine, Hangzhou, China.

^# Contributed equally.

Abstract

[Figure: see text].

Keywords: angiotensin II; angiotensinogen; fibroblasts; heart diseases; sepsis.